No Data
No Data
Insider Sale: CHIEF FINANCIAL OFFICER of $KNSA Sells 8,879 Shares
The tariff war between the US and Europe is escalating, and Trump's 'tariff big stick' is making the pharmaceutical industry tremble.
Pharmaceutical companies are urging the Trump administration and EU officials to exclude Medical products from the escalation of the trade war.
New York Manufacturing Hits Low, Inflation Fears Rise
Citi Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $40
Kiniksa Pharmaceuticals Analyst Ratings
Express News | Kiniksa Pharmaceuticals Ltd : Citigroup Initiates Coverage With Buy Rating; Price Target $40